PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas.

ABSTRACT:

Objective

The BRAF inhibitor, vemurafenib, has been widely used in the treatment of patients with melanoma-bearing BRAF^V600E mutations. While the initial response to vemurafenib is usually excellent, the majority of patients eventually develop resistance and metastatic disease. However, the underlying molecular mechanism remains elusive. The objective of this study was therefore to identify additional molecular targets responsible for vemurafenib resistance.

Methods

Western blots and immunohistochemistry analyses were used to evaluate expressions of PYK2 and p-PYK2 in cultured cells and melanoma tissue microarrays. The relationships of p-PYK2 with clinicopathological parameters were statistically analyzed. Invadopodia cell invasion, and a Ca²⁺ assay wer

SUBMITTER: Shen J 

PROVIDER: S-EPMC9425182 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature